[A study of XXXX levels in the cerebrospinal fluid of @entity1 with @entity1276 ].

@entity1 @entity1276 @entity548 @entity510 @entity2554 @entity281 @entity2891 @entity1779 @entity5579
Eleven neurosurgical @entity1 without @entity281 were given 4 g @entity2891 ( @entity5579 ) intravenously for 30 minutes. Ventricular drainage was performed in 10 cases, and 1 case with cisternal drainage. Eight of 11 cases showed moderate to severe @entity2554 . Serum and ventricular cerebrospinal fluid (CSF) concentrations of @entity5579 were measured for 8 hours after injection. Average peak serum concentration of @entity5579 was 476 micrograms/ml and the half-life was 150 minutes. @entity1 with obstructive @entity1276 showed relative good penetration of @entity5579 in CSF (2.74 approximately 5.29 micrograms/ml). Especially, those who had severe dilatation of ventricles demonstrated sequential increased concentration (5.48 approximately 6.25 micrograms/ml at 8 hours). In poor risk @entity1 and @entity1779 with @entity548 cases, who had normal range of CSF cell counts and protein, @entity5579 level was low, less than 2 micrograms/ml. In cases with severe @entity510 , sufficient concentration (11 micrograms/ml) of @entity5579 was observed in cisternal CSF. The @entity5579 concentrations in CSF after 4 g administration did not seem to exceed comparing to 2 g dosing.
